Processa Pharmaceuticals, Inc.

Contributing Author

Recent Articles by Processa Pharmaceuticals, Inc.

2 hours	PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREAS PCSA -34.10% GlobeNewswire
Jan-12	Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference PCSA -6.55% GlobeNewswire
Jan-05	Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study PCSA +10.24% GlobeNewswire
Dec-17	Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer PCSA +122.30% GlobeNewswire
Nov-05	Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025 PCSA GlobeNewswire
Aug-07	Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies PCSA GlobeNewswire
Jul-01	Processa Pharmaceuticals Provides Portfolio and Business Update PCSA GlobeNewswire
Jun-17	Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering PCSA +15.50% PCSA -6.92% GlobeNewswire
Jun-17	Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate PCSA +15.50% GlobeNewswire
Jun-13	Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025 PCSA -24.92% GlobeNewswire
May-30	Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting PCSA GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 1 minute for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)